questions remaining in the field of her2-low breast cancer
Published 1 year ago • 578 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
0:56
remaining questions on the management of her2-low breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
0:31
remaining questions regarding her2-low breast cancer
-
1:19
remaining challenges regarding her2-low breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
2:05
latest news in her2-low breast cancer
-
1:08
destiny-breast04: a ground-breaking trial in her2-low breast cancer
-
2:30
destiny-breast04: t-dxd in her2-low breast cancer regardless of molecular markers
-
1:36
is her2-low a distinct subtype of breast cancer?
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:16
her2-low expression in breast cancer
-
0:57
evaluating the benefits of selective cdk4 inhibition in hr /her2- breast cancer
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
2:21
adcs for the treatment of her2-low breast cancer
-
6:51
adcs for her2 and her2-low breast cancer